From the Editor

While Congress debates hundreds of healthcare plan proposals, perhaps we, the public, can get in the game too.

November is finally upon us and the days are getting colder and shorter.

Well, the summer's well and truly behind us and Madrid beckons for this year's CPhI Worldwide.

After years of promomting QbD concepts, FDA's ready to take action on nonconformers.

Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something.

Individuals and companies at the top seem to have no problem short-circuiting their success.

Is it good policy to pay for bad behavior?

You are invited to Link In and Twitter with PTE!

Misleading the public about their investments-be it money or medicine-is unacceptable.

This month, Frankfurt readies itself for the descent of more than 27000 additional visitors, as it plays host to the world's largest chemical engineering exhibition and congress - Achema 2009.

Obama's cost-containment and science-innovation initiatives need to overlap.

The financial and economic downturn is likey to have long-term implications for outsourcing.

The formation of a partnership, whether personal or professional, is risky business.

This month's editor's comment.

FDA's role should not be overlooked as it has been in years past.

January was another very bleak month financially, but luckily it ended on a bit of a political high...

The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.

Christmas is over. Everybody is back at work feeling a bit hungover, a lot poorer and alarmingly heavier...

The past year saw major acquisitions attempted, completed, rejected, and stalled.

China's quality approach to domestic versus exported products seems to be a lose-lose situation.

Pharma companies could benefit from the lessons learned in this fall's financial crisis.

The first 2 weeks of October witnessed the closure of CPhI (30 September–2 October) and the whole of Biotechnica (7–9 October). Pharmaceutical Technology Europe had a presence at both events, which took place in Frankfurt and Hanover (both Germany), respectively. With record-breaking numbers of attendees, roundtables and conferences of the highest quality, and exhibitors from bio and pharma companies from all over the world, these two events are a must in the calendars of many in the biotech and pharmaceutical industries.

Can previous trends of Democratic and Republican administrations predict industry's future?

Counterfeiting has become the topic of conversation at all levels of the pharmaceutical industry. Considering the rising number of cases, this is hardly surprising.

This year, the employment survey will acknowledge the industry's best employers.

Are hypersanitation trends a result of scaremongering or a lack of faith in medicine?

It's back to school. Another summer has flown past and here we all meet again, ready to return to work and face the winter with renewed energies. Welcome back!

Legislative decisions to increase Medicare's formulary may lead to a fight over drug approvals.

With no economic relief in sight, industry, like all of us, is grappling with high-and new-costs.

As summer approaches, the European pharmaceutical industry is preparing for a well-deserved break. However, some will leave the arena on a higher note than others. While big pharma is embracing the globalization of the industry and suffering under extreme pressure to improve performance, the biopharmaceutical sector retires with a smile and reasons to celebrate.